The benzodiazepine receptor antagonist, flumazenil does not block clinical effects of delta-9-tetrahydrocannabinol
- 1 January 1990
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 47 (18) , 1655-1660
- https://doi.org/10.1016/0024-3205(90)90371-w
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- FlumazenilDrugs, 1988
- The central neuropharmcology of psychotropic cannabinoidsPharmacology & Therapeutics, 1988
- Flumazenil in the management of acute drug overdosage with benzodiazepines and other agentsClinical Pharmacology & Therapeutics, 1987
- A Selective Imidazobenzodiazepine Antagonist of Ethanol in the RatScience, 1986
- The role of benzodiazepine receptors in the discriminative stimulus properties of delta-9-tetrahydrocannabinolLife Sciences, 1986
- Antianxiety effect of cannabis: Involvement of central benzodiazepine receptorsBiological Psychiatry, 1986
- Cannabinoids inhibit calcium uptake by brain synaptosomesJournal of Neuroscience, 1982
- Simultaneous reduction in the turnover rates of septal gamma-aminobutyric acid and hippocampal acetylcholine following administration of nabiloneNeuropharmacology, 1981
- Do Plasma Concentrations of Δ9‐Tetrahydrocannabinol Reflect the Degree of Intoxication?The Journal of Clinical Pharmacology, 1981
- Inhibition of prostaglandin E2 biosynthesis by Δ1-tetrahydrocannabinolProstaglandins, 1972